News

February 23, 2018February 23, 2018

New Guidelines Aim to Help Doctors Recognize, Manage Side Effects of Immune Checkpoint Inhibitors

News

The American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) recently developed a set of guidelines to serve as recommendations to clinicians regarding how to assess and ... Read more

February 22, 2018February 22, 2018

Incysus Reports Its Drug-Resistant Brain Cancer Immunotherapy Can Be Cold-preserved

News

Incysus’s drug-resistant brain cancer immunotherapy can be cold-preserved without losing its ability to fight tumors, the company reports. The finding adds to the attractiveness of its genetically engineered gamma-delta T-cell treatment for glioblastoma, ... Read more

February 21, 2018February 21, 2018

Imfinzi Is First Immunotherapy Approved for Advanced Non-small Cell Lung Cancer in US

News

Imfizi (durvalumab) has become the first approved immunotherapy in the United States for patients with advanced non-small cell lung cancer that has stabilized. The U.S. Food and Drug Admnistration authorization applies ... Read more

February 20, 2018February 20, 2018

Imfinzi Seen to Safely Help Certain Patients with Advanced Head and Neck Cancer in Phase 2 Trial

News

Data from the Phase 2 CONDOR trial continue to support the safety, and show some efficacy, of treatment with Imfinzi (durvalumab) in certain pre-treated patients with advanced head and neck cancer. ... Read more

February 19, 2018February 19, 2018

Opdivo Safe for Head and Neck Cancer Patients on Radiation and Chemo, Phase 1 Trial Shows

News

Adding Bristol-Myers-Squibb‘s Opdivo (nivolumab) to a regimen of radiation therapy and chemotherapy is safe in patients with newly diagnosed advanced head and neck cancer, a Phase 1 clinical trial shows. Researchers presented the ... Read more

February 16, 2018February 16, 2018

73% of Kidney Cancer Patients Respond to Inlyta-Keytruda Combo, Trial Shows

News

Seventy-three percent of patients with kidney cancer that appeared in other parts of their body after their main tumor had been removed responded to a combination of Inlyta (axitinib) and Keytruda (pembrolizumab), ... Read more

February 15, 2018February 15, 2018

More Than Half of Urothelial Cancer Patients Benefited from Tislelizumab in a Phase 1 Trial

News

BeiGene‘s investigational antibody tislelizumab was well-tolerated and induced at least stable disease in 53 percent of urothelial carcinoma patients treated in a Phase 1a/b clinical trial. The data was presented ... Read more

February 14, 2018February 14, 2018

Phase 2 Trial to Evaluate Combo of Imprime PGG, Keytruda in Head and Neck Cancer

News

Biothera Pharmaceuticals has begun treating patients in a Phase 2 clinical trial evaluating its Imprime PGG in combination with Merck’s Keytruda (pembrolizumab) for patients with advanced squamous cell carcinoma of ... Read more

February 13, 2018February 13, 2018

Targovax Therapy and Chemo Trigger Immune Response to Mesothelioma, Phase 1/2 Trial Shows

News

ONCOS-102 triggered an immune response against mesothelioma and was safe, the initial results of a Phase 1/2 clinical trial of a combo therapy shows. Targovax designed its virus-based ONCOS-102 to strengthen the ... Read more

February 12, 2018February 12, 2018

Tecentriq-Avastin Combo Keeps Advanced Kidney Cancer in Check, Roche Says

News

Treatment with Tecentriq (atezolizumab) and Avastin (bevacizumab) reduces the risk that advanced kidney cancer patients’ disease will get worse, concludes a Phase 3 study by Roche. The Swiss pharma giant ... Read more